文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

GM-CSF抑制可减少异种移植模型中的细胞因子释放综合征和神经炎症,但增强CAR-T细胞功能

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
PubMed 文献 · Blood · 2018-11-21

本研究探讨中和粒细胞-巨噬细胞集落刺激因子(GM-CSF)作为管理CD19靶向CAR-T(CART19)细胞相关毒性策略的潜力。在患者来源异种移植模型中,使用lenzilumab中和GM-CSF不影响CART19细胞功能,增强其增殖并更好维持对白血病的持久控制;在急性淋巴细胞白血病异种移植CRS和神经炎症模型中,GM-CSF中和减少中枢神经系统髓系和T细胞浸润,显著减少神经炎症并预防CRS。通过CRISPR/Cas9破坏GM-CSF生成的GM-CSFk/o CAR-T细胞维持正常功能,体内抗肿瘤活性增强,总生存期改善。

要点

  • lenzilumab中和GM-CSF不影响CART19细胞体外或体内功能。
  • GM-CSF中和减少异种移植模型中枢神经系统髓系和T细胞浸润,显著减少神经炎症并预防CRS。
  • GM-CSFk/o CAR-T细胞维持正常功能,体内抗肿瘤活性增强,总生存期改善。

核心结论

  • 这些研究阐明了一种通过GM-CSF中和来消除神经炎症和CRS的新方法,可能潜在增强CAR-T细胞功能。
  • 计划开展lenzilumab联合CART19细胞治疗的2期研究。

研究设计与样本

  • 研究包括体外实验、患者来源异种移植模型、患者急性淋巴细胞白血病异种移植CRS和神经炎症模型,以及通过CRISPR/Cas9生成GM-CSF缺陷型CART19细胞。

主要发现

  • 使用lenzilumab中和GM-CSF不影响CART19细胞体外或体内功能。
  • 在患者来源异种移植中,GM-CSF中和后CART19细胞增殖增强,对白血病的持久控制更好。
  • 在患者急性淋巴细胞白血病异种移植CRS和神经炎症模型中,GM-CSF中和导致中枢神经系统髓系和T细胞浸润减少,神经炎症显著减少并预防CRS。
  • GM-CSFk/o CAR-T细胞维持正常功能,体内抗肿瘤活性增强,总生存期改善,与CART19细胞相比。

关键数值与推荐

  • 原文未报告具体数值标准或推荐等级。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited by the associated toxicities. These include cytokine release syndrome (CRS) and neurotoxicity. Although the IL-6R antagonist tocilizumab is approved for treatment of CRS, there is no approved treatment of neurotoxicity associated with CD19-targeted CAR-T (CART19) cell therapy. Recent data suggest that monocytes and macrophages contribute to the development of CRS and neurotoxicity after CAR-T cell therapy. Therefore, we investigated neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) as a potential strategy to manage CART19 cell-associated toxicities. In this study, we show that GM-CSF neutralization with lenzilumab does not inhibit CART19 cell function in vitro or in vivo. Moreover, CART19 cell proliferation was enhanced and durable control of leukemic disease was maintained better in patient-derived xenografts after GM-CSF neutralization with lenzilumab. In a patient acute lymphoblastic leukemia xenograft model of CRS and neuroinflammation (NI), GM-CSF neutralization resulted in a reduction of myeloid and T cell infiltration in the central nervous system and a significant reduction in NI and prevention of CRS. Finally, we generated GM-CSF-deficient CART19 cells through CRISPR/Cas9 disruption of GM-CSF during CAR-T cell manufacturing. These GM-CSFk/o CAR-T cells maintained normal functions and had enhanced antitumor activity in vivo, as well as improved overall survival, compared with CART19 cells. Together, these studies illuminate a novel approach to abrogate NI and CRS through GM-CSF neutralization, which may potentially enhance CAR-T cell function. Phase 2 studies with lenzilumab in combination with CART19 cell therapy are planned.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2018. PMID: 30463995. doi:10.1182/blood-2018-10-881722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。